RxDoctor Payments Data

Andrejs Belovs, PA

Physician Assistant · Fort Myers, FLNPI 1285063677

Payments from drug & device makers

$1,019in general payments, 2019–2025

Across 38 payments — averaging $26.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$590
  • AstraZeneca$198
  • Boehringer Ingelheim$150
  • Grifols USA, LLC$44
  • Boston Scientific$22
  • Inspire Medical Systems, Inc.$14

What the payments were for

  • Food & beverage$1,019100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,019 in reported general payments places this provider in the 60th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$37,446
Medicare patients
198
Services billed
612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter368$441,671
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr197$192,268
Spiriva RespimatTiotropium Bromide125$142,247
SymbicortBudesonide/Formoterol Fumarate264$137,207
Stiolto RespimatTiotropium Br/Olodaterol Hcl128$135,104
Breo ElliptaFluticasone/Vilanterol134$98,717
Breztri AerosphereBudesonide/Glycopyr/Formoterol63$79,368
Dupixent PenDupilumab12$51,541
Dupixent SyringeDupilumab12$44,453
Combivent RespimatIpratropium/Albuterol Sulfate27$32,085
Albuterol Sulfate HfaAlbuterol Sulfate936$30,799
Spiriva HandihalerTiotropium Bromide21$22,768
Bevespi AerosphereGlycopyrrolate/Formoterol Fum21$16,994
Ventolin HfaAlbuterol Sulfate147$16,303
Azelastine-FluticasoneAzelastine/Fluticasone40$11,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$590$741,722718 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$150$309,436280 claims
AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere$198$233,569348 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →